EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Preoperative chemoradiotherapy with the TEGAFIRI regimen achieves significant local control in locally advanced rectal cancer

Shigenobu Emoto, Kazushige Kawai, Koji Oba, Hiroaki Nozawa, Kazuhito Sasaki, Koji Murono, Yuichiro Yokoyama, Shinya Abe, Kensuke Kaneko, Yuzo Nagai, Takahide Shinagawa, Yuichi Tachikawa und 2 weitere

International Journal of Colorectal Disease · 2025

DOI: 10.1007/s00384-025-04867-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Colorectal Disease, 2025. Verfasst von Shigenobu Emoto und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology, The University of Tokyo, 7-3-1, Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan. emotos-sur@h.u-tokyo.ac.jp. Hauptthemen laut MEDLINE: Rectal Neoplasms, Tegafur, Chemoradiotherapy, Preoperative Care. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, The University of Tokyo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study aims to evaluate both the short- and long-term outcomes of preoperative chemoradiotherapy (CRT) using the tegafur-uracil/calcium folinate/irinotecan (TEGAFIRI) regimen in patients with locally advanced rectal cancer (LARC). While total neoadjuvant therapy (TNT) is becoming more common, CRT may still be the optimal approach in certain cases to improve prognosis and reduce adverse events.

Methods

This single-center, retrospective cohort study included patients with histologically confirmed nonmetastatic primary adenocarcinoma of the lower rectum treated with preoperative CRT using the TEGAFIRI regimen (TEGAFIRI group). The control group comprised patients treated with tegafur-uracil/calcium folinate (UFT group). The primary endpoint was the pathologic complete response (pCR) rate. Secondary endpoints included adverse events, overall survival (OS), disease-free survival (DFS), distant recurrence-free survival (DRFS), and local recurrence-free survival (LRFS). The background was adjusted using inverse probability weighting (IPW) calculated with the propensity score.

Results

The TEGAFIRI group consisted of 79 patients, while the UFT group included 264. The standardized pCR rates through the IPW were as follows: TEGAFIRI group: 24.3%, UFT group: 8.8%, and the difference in pCR was 15.4% ( P = 0.01). Adverse events of grade 3 or higher were observed in 15.2% vs. 8.7% (adjusted) (13.6% vs. 9.1% crude) in the TEGAFIRI group and the UFT group. The standardized LRFS was significantly higher in the TEGAFIRI group (HR = 0.39, (95% CI 0.16–0.98), P = 0.045). There were no significant differences in OS, DFS, or DRFS between groups.

Conclusions

The TEGAFIRI regimen for preoperative CRT in LARC demonstrated a high pCR rate and reduced local recurrence, with manageable adverse events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rectal NeoplasmsTegafurChemoradiotherapyPreoperative CareAntineoplastic Combined Chemotherapy ProtocolsCamptothecinHumansMaleFemaleMiddle AgedAgedIrinotecanDisease-Free SurvivalTreatment OutcomeNeoplasm Recurrence, LocalNeoadjuvant TherapyLeucovorinRetrospective StudiesAdult

Stichwörter der Autor:innen

Locally advanced rectal cancerPreoperative chemoradiotherapyTEGAFIRI regimen

Substanzen

TegafurIrinotecanCamptothecinLeucovorin

Autor:innen und Institutionen

  • Department of Surgical Oncology, The University of Tokyo, 7-3-1, Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan. emotos-sur@h.u-tokyo.ac.jp.
  • Department of Surgery, Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, Tokyo, Japan.
  • Department of Biostatistics, The University of Tokyo, Tokyo, Japan.
  • Department of Surgical Oncology, The University of Tokyo, 7-3-1, Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.

Förderung

  • Japan Society for the Promotion of Science
  • The University of Tokyo

Zitieren

APA

Emoto, S., Kawai, K., Oba, K., Nozawa, H., Sasaki, K., Murono, K., Yokoyama, Y., Abe, S., Kaneko, K., Nagai, Y., Shinagawa, T., Tachikawa, Y., Okada, S., & Ishihara, S. (2025). Preoperative chemoradiotherapy with the TEGAFIRI regimen achieves significant local control in locally advanced rectal cancer. International Journal of Colorectal Disease. https://doi.org/10.1007/s00384-025-04867-0

Vancouver

Emoto S, Kawai K, Oba K, Nozawa H, Sasaki K, Murono K, et al. Preoperative chemoradiotherapy with the TEGAFIRI regimen achieves significant local control in locally advanced rectal cancer. International Journal of Colorectal Disease. 2025. doi:10.1007/s00384-025-04867-0

BibTeX
@article{Emoto2025,
  author = {Emoto, Shigenobu and Kawai, Kazushige and Oba, Koji and Nozawa, Hiroaki and Sasaki, Kazuhito and Murono, Koji and Yokoyama, Yuichiro and Abe, Shinya and Kaneko, Kensuke and Nagai, Yuzo and Shinagawa, Takahide and Tachikawa, Yuichi and Okada, Satoshi and Ishihara, Soichiro},
  title = {Preoperative chemoradiotherapy with the TEGAFIRI regimen achieves significant local control in locally advanced rectal cancer},
  journal = {International Journal of Colorectal Disease},
  year = {2025},
  doi = {10.1007/s00384-025-04867-0}
}
Kostenlos starten →